Targeted Therapy for Triple-Negative Breast Cancer: A Comprehensive Review of Emerging Strategies

Hok Shui'

Department of Clinical Oncology, University of Hong Kong, Hong Kong, China

'Corresponding author: Hok shui, Department of Clinical Oncology, University of Hong Kong, Hong Kong, China, E-mail: Cheu@jac.cn

Received: 26-Jun-2024, Manuscript No. AOT-24-142742; **Editor assigned:** 28-Jun-2024, PreQ No. AOT-24-142742 (PQ); **Reviewed:** 12-Jul-2024, QC No. AOT-24-142742; **Revised:** 19-Jul-2024, Manuscript No. AOT-24-142742 (R); **Published:** 26-Jul-2024, DOI: 10.4172/aot.1000292

Citation: Shui H (2024) Targeted Therapy for Triple-Negative Breast Cancer: A Comprehensive Review of Emerging Strategies. J Oncol Res Treat 9:292.

Copyright: © 2024 Shui H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Description

Triple-Negative Breast Cancer (TNBC) is a very aggressive subtype of breast cancer that is distinguished by the lack of Human Epidermal Growth Factor Receptor 2 (HER2), Progesterone Receptors (PR) and Estrogen Receptors (ER). TNBC's lack of receptors renders it resistant to HER2-targeted therapies and hormone therapy, which poses a major management problem. Effective targeted therapy for TNBC is therefore desperately needed. In this paper, new approaches to targeted therapy for TNBC are reviewed with an emphasis on their mechanisms, clinical utility and future directions.

VPBC ocmgu wr 10%-20% qh cm dtgcuv ecpegt ecugu cpf ku oqtg eqooqp kp Ahtkeep Aogtkeep epf {qwpigt yqogp. Ykvj c tepig qh igpgyke cpf grkigpgyke ejcpigu, ky ku v{rkhkgf d{ eqpukfgtcdng o qngewnct jgvgtqigpgkv{. Vjgug eqortkug ejcpigu vq rcvjyc{u nkmg RI3M/AMV/ oVQT cpf OARM, cu ygnn cu owvevkqpu kp igpgu nkmg TP53 cpf BRCA1/2. Y jgp eqorctgf vq qvjgt dtgcuv ecpegt uwdv{rgu, VPBC jcu c yqtug rtqipquku cpf c itgcvgt tgewttgpeg tcvg fwg vq kvu jkij o qngewnct xctkgv{ cpf ncem qh urgekhke tgegrvqtu, y jkej o cmg vtgcv o gpv oqtg fkhhkewnv. Ipjkdkvqtu qh Rqn{ (Afr-Tkdqug) Rqn{ ogtcug (RATR) jexg fgoqpuvtevgf rqvgpvken kp vjg vtgevogpv qh Vtkrng Pgievkxg Btgeuv Ccpegt (VPBC), gurgekenn{ kp kpfkxkfwcnu ykvj BRCA1/2 o wycykqpu. Ap gp|{og ecmgf RATR ku guugpvkcn kp DPA tgrckt; yjgp kv ku kpjkdkvgf, DPA fcocig dwknfu wr cpf gxgpvwcm{ tguwnvu kp ecpegt egnn fgcvj. A oclqt fgxgnqrogpv kp vjg vtgcvogpv qh BRCA-owvcvgf dtgcuv ecpegt jcu dggp vjg crrtqxcn qh RATR kpjkdkvqtu uwej cu qncrctkd cpf vcnc|qrctkd. Iortqxgf Rtqitguukqp-Ftgg Uwtxkxcn (RFU) kp rcvkgpvu ykvj VPBC yjq ectt{ c BTCA o wvcvkqp jcu dggp vjg tguwnv qh enkpkecn vtkcnu fgoqpuvtcvkpi vjgkt ghhgevkxgpguu.

VPBC rcvkgpvu oc{ dgpghkv _ ep

Citation: Shui H (2024) Targeted Therapy for Triple-Negative Breast Cancer: A Comprehensive Review of Emerging Strategies. J Oncol Res Treat. 9: 292.

Page 2 of 2

TNBC biology expands, more tailored and efficient treatments will be made available, giving individuals fighting this aggressive illness newfound hope.